Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) Stock Competitors & Peer Comparison

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, RPRX has a market cap of 25.9B. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while RPRX trades at $58.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas RPRX's P/E ratio is 11.13. In terms of profitability, KNSA's ROE is +0.14%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, KNSA is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check RPRX's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, CORT has a market cap of 11.9B. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while CORT trades at $110.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas CORT's P/E ratio is 315.11. In terms of profitability, KNSA's ROE is +0.14%, compared to CORT's ROE of +0.08%. Regarding short-term risk, KNSA is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CORT's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas WBA's P/E ratio is -1.64. In terms of profitability, KNSA's ROE is +0.14%, compared to WBA's ROE of -0.57%. Regarding short-term risk, KNSA is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check WBA's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, LQDA has a market cap of 5.9B. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while LQDA trades at $66.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas LQDA's P/E ratio is 477.71. In terms of profitability, KNSA's ROE is +0.14%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, KNSA is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check LQDA's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, PBH has a market cap of 2.1B. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while PBH trades at $44.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas PBH's P/E ratio is 10.17. In terms of profitability, KNSA's ROE is +0.14%, compared to PBH's ROE of +0.09%. Regarding short-term risk, KNSA is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check PBH's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas HROWL's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, KNSA is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check HROWL's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, LTGO has a market cap of 1.4B. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while LTGO trades at $22.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas LTGO's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to LTGO's ROE of N/A. Regarding short-term risk, KNSA is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check LTGO's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas HROWM's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, KNSA is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check HROWM's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, HELP has a market cap of 766.7M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while HELP trades at $12.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas HELP's P/E ratio is -2.97. In terms of profitability, KNSA's ROE is +0.14%, compared to HELP's ROE of -0.71%. Regarding short-term risk, KNSA is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check HELP's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while SVA trades at $6.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas SVA's P/E ratio is -5.68. In terms of profitability, KNSA's ROE is +0.14%, compared to SVA's ROE of -0.01%. Regarding short-term risk, KNSA is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check SVA's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, CUVL has a market cap of 297.5M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while CUVL trades at $5.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas CUVL's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to CUVL's ROE of N/A. Regarding short-term risk, KNSA is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check CUVL's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, CELG-RI has a market cap of 242.7M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while CELG-RI trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, KNSA is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CELG-RI's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, HITI has a market cap of 226.7M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while HITI trades at $2.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas HITI's P/E ratio is -7.57. In terms of profitability, KNSA's ROE is +0.14%, compared to HITI's ROE of -0.36%. Regarding short-term risk, KNSA is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check HITI's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, CTOR has a market cap of 106M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while CTOR trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas CTOR's P/E ratio is -2.43. In terms of profitability, KNSA's ROE is +0.14%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, KNSA is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CTOR's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while ATLN trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas ATLN's P/E ratio is -0.68. In terms of profitability, KNSA's ROE is +0.14%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, KNSA is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check ATLN's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, SDEV has a market cap of 52.2M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while SDEV trades at $1.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas SDEV's P/E ratio is -0.18. In terms of profitability, KNSA's ROE is +0.14%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, KNSA is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SDEV's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas RAD's P/E ratio is -0.05. In terms of profitability, KNSA's ROE is +0.14%, compared to RAD's ROE of +2.76%. Regarding short-term risk, KNSA is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check RAD's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas GLTO's P/E ratio is -1.78. In terms of profitability, KNSA's ROE is +0.14%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, KNSA is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check GLTO's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, NSRX has a market cap of 29.7M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while NSRX trades at $3.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas NSRX's P/E ratio is -4.78. In terms of profitability, KNSA's ROE is +0.14%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, KNSA is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check NSRX's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, SCYX has a market cap of 28M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while SCYX trades at $4.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas SCYX's P/E ratio is -1.30. In terms of profitability, KNSA's ROE is +0.14%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, KNSA is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SCYX's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, COSM has a market cap of 17.9M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while COSM trades at $0.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas COSM's P/E ratio is -0.45. In terms of profitability, KNSA's ROE is +0.14%, compared to COSM's ROE of -1.19%. Regarding short-term risk, KNSA is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check COSM's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, BFRI has a market cap of 16.9M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while BFRI trades at $1.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas BFRI's P/E ratio is -2.40. In terms of profitability, KNSA's ROE is +0.14%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, KNSA is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BFRI's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, CNSY has a market cap of 14M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while CNSY trades at $2.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas CNSY's P/E ratio is -0.48. In terms of profitability, KNSA's ROE is +0.14%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, KNSA is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CNSY's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, SCNX has a market cap of 12.7M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while SCNX trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas SCNX's P/E ratio is -0.15. In terms of profitability, KNSA's ROE is +0.14%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, KNSA is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SCNX's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, BFRIW has a market cap of 11.4M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while BFRIW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, KNSA's ROE is +0.14%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, KNSA is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check BFRIW's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas CJJD's P/E ratio is -0.46. In terms of profitability, KNSA's ROE is +0.14%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, KNSA is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CJJD's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas SSY's P/E ratio is -2.86. In terms of profitability, KNSA's ROE is +0.14%, compared to SSY's ROE of -0.09%. Regarding short-term risk, KNSA is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SSY's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, POM has a market cap of 5.4M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while POM trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas POM's P/E ratio is -0.16. In terms of profitability, KNSA's ROE is +0.14%, compared to POM's ROE of +0.16%. Regarding short-term risk, KNSA is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check POM's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, BGMS has a market cap of 5.2M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while BGMS trades at $0.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas BGMS's P/E ratio is -0.26. In terms of profitability, KNSA's ROE is +0.14%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, KNSA is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BGMS's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, PAVS has a market cap of 3.5M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while PAVS trades at $4.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas PAVS's P/E ratio is -0.05. In terms of profitability, KNSA's ROE is +0.14%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, KNSA is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check PAVS's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, EOCN has a market cap of 3.5M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while EOCN trades at $3.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas EOCN's P/E ratio is -0.24. In terms of profitability, KNSA's ROE is +0.14%, compared to EOCN's ROE of N/A. Regarding short-term risk, KNSA is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check EOCN's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas MDVL's P/E ratio is -0.05. In terms of profitability, KNSA's ROE is +0.14%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, KNSA is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check MDVL's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas ATNFW's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, KNSA is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check ATNFW's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, KNSA's ROE is +0.14%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, KNSA is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BGMSP's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas AZNH's P/E ratio is 38.35. In terms of profitability, KNSA's ROE is +0.14%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, KNSA is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check AZNH's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, KNSA's ROE is +0.14%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, KNSA is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check LFLYW's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, PRPH has a market cap of 175.2K. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while PRPH trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas PRPH's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, KNSA is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check PRPH's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, CPD has a market cap of 0. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas CPD's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to CPD's ROE of N/A. Regarding short-term risk, KNSA is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check CPD's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas SHPG's P/E ratio is 11.35. In terms of profitability, KNSA's ROE is +0.14%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, KNSA is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check SHPG's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, POZN has a market cap of 0. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas POZN's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to POZN's ROE of +0.61%. Regarding short-term risk, KNSA is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check POZN's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, OREX has a market cap of 0. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas OREX's P/E ratio is -0.14. In terms of profitability, KNSA's ROE is +0.14%, compared to OREX's ROE of -0.54%. Regarding short-term risk, KNSA is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check OREX's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas IPXL's P/E ratio is -10.11. In terms of profitability, KNSA's ROE is +0.14%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, KNSA is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check IPXL's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 5.9B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, KNSA is priced at $77.24 on the NASDAQ, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 85.82, whereas ESRX's P/E ratio is 10.69. In terms of profitability, KNSA's ROE is +0.14%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, KNSA is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check ESRX's competition here